Prof.Kamaljeet Singh, K03716
Too many side effects are reported of intravitreal triamcinolone (IVTA} after use of 4mg IVTA. The study was done to see the safety profile of IVTA in patients of diabetic macular oedema (DME) presenting to a tertiary care hospital. Of the 125 patients, 5 opted for ranibizumab and 120 triamcinolone. These 120 were included in the study and received 0.05ml (2mg) of preservative free IVTA after controlling the diabetes. Base line visual acuity (ETDRS), cataract progression, IOP, OCT for central macular thickness (CMT) were recorded and followed up weekly, monthly and then six monthly for 2 years. Complications were noted.
Results: Visual acuity improved to 6 to 9 letters, cataract progression seen in 1 (.008%), IOP rise in 2/120 (.002%) ; mean reduction in CMT was 188 micron. It remained reduced till 8 to 12 weeks. Endophthalmitis was seen in none.
Conclusion: IVTA 2mg can be given safely in DME with good outcome and insignificant complications.
Leave a Comment